Review: platelet immunology—similarities and differences with red cell immunology
By:
Paid access
|Nov 2020References
- Lewis M, Anstee DJ, Bird GWG, et al. Blood group terminology 1990. Vox Sang 1990;58:152–69.
- Mueller-Eckhardt C. Platelet allo- and autoantigens and their clinical implications. In: Nance SJ, ed. Transfusion medicine in the 1990’s. Arlington, VA: American Association of Blood Banks, 1990:63–92.
- Mueller-Eckhardt C, Kiefel V, Santoso S. Review and update of platelet alloantigen systems. Transfus Med Rev 1990;IV:98–109.
- Williamson LM, Bruce D, Lubenko A, Chana HJ, Ouwehand WH. Molecular biology for platelet alloantigen typing. Transfus Med 1992;2:255–64.
- ICSH/ISBT Working Party on Platelet Serology. Nomenclature of platelet-specific antigens. Vox Sang 1990;58:176.
- von dem Borne AEGKr, Kaplan C, Minchinton R. Nomenclature of human platelet alloantigens. Blood 1995;85:1409–10.
- Newman PJ. Nomenclature of human platelet alloantigens: a problem with the HPA system? Blood 1994;83:1447–51.
- Shulman NR, Reid DM. Platelet immunology. In: Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. Hemostasis and thrombosis: basic principles and clinical practice. 3rd ed. Philadelphia: Lippincott, 1994:414–67.
- Garratty G. Factors affecting the pathogenicity of red cell auto- and alloantibodies. In: Nance SJ, ed. Immune destruction of red blood cells. Arlington, VA: American Association of Blood Banks, 1989:109–69.
- Aster RH. The immunologic thrombocytopenias. In: Kunicki TJ, George JN, eds. Platelet immunobiology. Philadelphia: Lippincott, 1989;387–435.
- Boshkov LK, Kelton JG. Use of intravenous gammaglobulin as an immune replacement and an immune suppressant. Transfus Med Rev 1980;III:82–120.
- Björokholm M. Intravenous immunoglobulin treatment in cytopenic haematological disorders. J Int Med 1993;234: 119–26.
- Bussel JB, McFarland JG, Berkowitz RL. Antenatal management of fetal alloimmune and autoimmune thrombocytopenia. Tranfus Med Rev 1990;IV:149–62.
- Kroll H, Kiefel V, Giers G, et al. Maternal intravenous immunoglobulin treatment does not prevent intracranial haemorrhage in fetal alloimmune thrombocytopenia. Transfus Med 1994;4:293–6.
- Schiffer CA, Hogge DE, Aisner J, et al. High-dose intravenous gammaglobulin in alloimmunized platelet transfusion recipients. Blood 1984;64:937–40.
- Kekomäki R, Elfenbein G, Gardner R, et al. Improved response of patients to refractory random-donor platelet transfusions by intravenous gamma globulin. Am J Med 1984;76:199–203.
- Zeigler ZR, Shadduck RK, Rosenfeld CS, et al. High-dose gamma globulin improves responses to single-donor platelets in patients refractory to platelet transfusions. Blood 1987;70: 1433–6.
- Zeigler ZR, Shadduck RK, Rosenfeld CS, et al. Intravenous gamma globulin decreases platelet-associated IgG and improves transfusion responses in platelet refractory states. Am J Hematol 1991;38:15–23.
- Heddle NM, Klama L, Kelton JG, et al. The use of anti-D to improve posttransfusion platelet response: a randomized trial. Br J Haematol 1995;89:163–8.
- Jungi TW, Nydegger UE. Proposed mechanisms of action in intravenous IgG (IVIG) in autoimmune diseases. Trans Sci 1992;13:267–90.
- Salama A, Mueller-Eckhardt C. Use of Rh antibodies in the treatment of autoimmune thrombocytopenia. Transfus Med Rev 1992;VI:17–25.
- Vengelen-Tyler V, Rodberg K, Nelson J. The effect of intravenous immune globulin (IVIG) on a solid phase platelet antibody test. International Society of Blood Transfusion/American Association of Blood Banks 1990 Joint Congress, Book of Abstracts:75.
- Lichtiger B, Rogge K. Spurious serologic test results in patients receiving infusions of intravenous immune gammaglobulin. Arch Pathol Lab Med 1991;115:467–9.
- Mueller-Eckhardt C, Kiefel V. Laboratory methods for the detection of platelet antibodies and identification of antigens. In: Kunicki TJ, George JN, eds. Platelet immunobiology. Philadelphia: Lippincott, 1989:436–53.
- Kurata Y, Oshida M, Take H, et al. Acid treatment of platelets as a simple procedure for distinguishing platelet-specific antibodies from anti-HLA antibodies: comparison with chloroquine treatment. Vox Sang 1990;59:106–11.
- Neumüller J, Tohidast-Akrad M, Fischer M, Mayr WR. Influence of chloroquine or acid treatment of human platelets on the antigenicity of HLA and the “Thrombocyte-Specific” glycoproteins Ia/IIa, IIb, and IIb/IIIa. Vox Sang 1993;223–31.
- Kiefel V. The MAIPA assay and its applications in immunohematology. Transfus Med 1993;2:181–8.
- Freedman J, Hornstein A. Simple method for differentiating between HLA and platelet-specific antibodies by flow cytometry. Am J Hematol 1991;38:314–20.
- Waters AH. Autoimmune thrombocytopenia: clinical aspects. Sem Hematol 1992;29:18–25.
- George JN. Platelet immunoglobulin G: its significance for the evaluation of thrombocytopenia and for understanding the origin of
α -granule protein. Blood 1990;76:859–70. - Mueller-Eckhardt C, Kayser W, Mersch-Baumert K, et al. The clinical significance of platelet-associated IgG: a study on 298 patients with various disorders. Br J Haematol 1980;46:123–31.
- Kelton JG, Powers PJ, Carter CJ. A prospective study of the usefulness of the measurement of platelet-associated IgG for the diagnosis of idiopathic thrombocytopenic purpura. Blood 1982;60:1050–3.
- Court WS, Bozeman JM, Soong S-J, Saleh MN, Shaw DR, LoBuglio AF. Platelet surface-bound IgG in patients with immune and nonimmune thrombocytopenia. Blood 1987;69: 278–83.
- LoBuglio AF, Court WS, Vinocur L, Maglott G, Shaw GM. Immune thrombocytopenic purpura. Use of a 125I-labeled antihuman IgG monoclonal antibody to quantify platelet-blood IgG. N Engl J Med 1983;309:459.
- Kaplan HS, Garratty G. Predictive value of direct antiglobulin test results. Diag Med 1985;8:29–33.
- Garratty G. Target antigens for red-cell-bound autoantibodies. In: Nance SJ, ed. Clinical and basic science aspects of immunohematology. Arlington, VA: American Association of Blood Banks, 1991:33–72.
- Aster RH. Platelet-specific alloantigen systems: history, clinical significance and molecular biology. In: Nance SJ, ed. Alloimmunity: 1993 and beyond. Bethesda, MD: American Association of Blood Banks, 1993:83–116.
- Goldman M, Filion M, Prouix C, Chartrand P, Décary F. Neonatal alloimmune thrombocytopenia. Transfus Med Rev 1994;VIII:123–31.
- Lalezari P, Dmitrova A, Diwan A, Einarson M. HLA incompatibility is the most common cause of alloimmune neonatal thrombocytopenia (ANT) (abstract). Blood 1993;82:203a.
- Lalezari P. HLA incompatibility in neonatal alloimmune thrombocytopenia. Transfus Today 1994;21:6–8.
- McFarland JG, Frenzke M, Aster RH. Testing of maternal sera in pregnancies at risk for neonatal alloimmune thrombocytopenia. Transfusion 1989;29:128–33.
- Valentin N, Vergracht A, Bignon JD, et al. HLA-DRw52a is involved in alloimmunization against PlA1 antigen. Hum Immunol 1990;27:73–6.
- Reesink HW, Engelfriet CP. Prenatal management of fetal alloimmune thrombocytopenia. Vox Sang 1993;65:180–9.
- Flug F, Karpatkin M, Karpatkin S. Should all pregnant women be tested for their platelet PLA (Zw, HPA-1) phenotype? Br J Haematol 1994;86:1–5.
- Doughty HA, Murphy MF, Metcalfe P, Waters AH. Antenatal screening for fetal alloimmune thrombocytopenia: the results of a pilot study. Br J Haematol 1995;90:321–5.
- Panzer S, Auerbach L, Cechova E, et al. Maternal alloimmunization against fetal platelet antigens: a prospective study. Br J Haematol 1995;90:655–60.
- Ness PM, Shirey RS, Thomas SK, Buck SA. The differentiation of delayed serologic and delayed hemolytic transfusion reactions: incidence, long-term serologic findings, and clinical significance. Transfusion 1990;30:688–93.
- Salama A, Mueller-Eckhardt C. Delayed hemolytic transfusion reactions. Transfusion 1984;24:188–93.
- Petz LD. The expanding boundaries of transfusion medicine. In: Nance SJ, ed. Clinical and basic science aspects of immunohematology. Arlington, VA: American Association of Blood Banks, 1991:73–113.
- Salama A, Mueller-Eckhardt C. Immune-mediated blood cell dyscrasias related to drugs. Sem Hematol 1992;29:53–63.
- Shulman NR, Reid DM. Mechanisms of drug-induced immunologically mediated cytopenias. Tranfus Med Rev 1993;VII:215–29.
- George JN, El-Harake MA, Aster RH. Thrombocytopenia due to enhanced platelet destruction by immunologic mechanisms. In: Beutler E, Lichtman MA, Coller BS, Kipps TJ, eds. Williams Hematology. 5th ed. New York: McGraw-Hill, 1995:1315–33.
- McFarland JG. Laboratory investigation of drug-induced immune thrombocytopenia. Transfus Med Rev 1993;VII: 275–87.
- Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Eng J Med 1995;332:1330–5.
- Visentin GP, Ford SE, Scott JP, Aster RH. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest 1994;93:81–8.
- Kelton JG, Smith JW, Warkentin TE, et al. Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4. Blood 1994; 83:3232–9.
- Chong BH. Heparin-induced thrombocytopenia. Br J Haematol 1995;89:431–9.
- Slichter SJ. Alloimmune refractoriness to transfused platelets. In: Garratty G, ed. Immunobiology of tranfusion medicine. New York: Dekker, 1994:597–627.
- Bishop JF, McGrath K, Wolf MM, et al. Clinical factors influencing the efficacy of pooled platelet transfusions. Blood 1988;71:383–7.
- Doughty HA, Murphy MF, Metcalfe P, et al. Relative importance of immune and non-immune causes of platelet refractoriness. Vox Sang 1994;66:200–5.
- Friedberg RC, Donnelly SF, Boyd JC, Gray LS, Mintz PD. Clinical and blood bank factors in the management of platelet refractoriness and alloimmunization. Blood 1993;81:3428–34.
- Dutcher JP, Schiffer CA, Aisner J, Wiernik PH. Alloimmunization following platelet transfusion: the absence of a dose-response relationship. Blood 1981;57:395–8.
- Murphy MF, Waters AH. Platelet transfusion: the problem of refractoriness. Blood Rev 1990;4:16–24.
- Langenscheidt F, Kiefel V, Santoso S, Mueller-Eckhardt C. Platelet transfusion refractoriness associated with two rare platelet-specific alloantibodies (anti-Baka and anti-PlA2) and multiple HLA antibodies. Transfusion 1988;28:597–600.
- Saji H, Maruya E, Fujii H, et al. New platelet antigen, Siba, involved in platelet transfusion refractoriness in a Japanese man. Vox Sang 1989;56:283–7.
- Ikeda H, Mitani T, Ohnuma M, et al. A new platelet-specific antigen, Naka, involved in the refractoriness of HLA-matched platelet transfusion. Vox Sang 1989;57:213–7.
- von dem Borne AEGKr, Ouwehand WH, Kuijpers RWAM. Theoretic and practical aspects of platelet crossmatching. Transfus Med Rev 1990;IV:265–78.
- Duquesnoy RJ, Anderson AJ, Tomasulo PA, Aster RH. ABO compatibility and platelet tranfusions of alloimmunized thrombocytopenic patients. Blood 1979;54:595–9.
- Brand A, Sintnicolaas K, Claas FHJ, Eernisse JG. ABH antibodies causing platelet transfusion refractoriness. Transfusion 1986;26:463–6.
- Heal JM, Blumberg N, Masel D. An evaluation of crossmatching, HLA, and ABO matching for platelet transfusions to refractory patients. Blood 1987;70:23–30.
- Lee EJ, Schiffer CA. ABO compatibility can influence the results of platelet transfusion. Transfusion 1989;29:384–9.
- Carr R, Hutton JL, Jenkins JA, Lucas GF, Amphlett NW. Transfusion of ABO-mismatched platelets leads to early platelet refractoriness. Br J Haematol 1990;75:408–13.
- Ogasawara K, Ueki J, Takenaka M, Furihata K. Study on the expression of ABH antigens on platelets. Blood 1993;82: 993–9.
- Heal JM, Rowe JM, McMican A, Masel D, Finke C, Blumberg N. The role of ABO matching in platelet transfusion. Eur J Haematol 1993;50:110–7.
- Heal JM, Rowe JM, Blumberg N. ABO and platelet transfusion revisited. Ann Hematol 1993;66:309–14.
- Heal JM, Masel D, Rowe JM, Blumberg N. Circulating immune complexes involving the ABO system after platelet transfusion. Br J Haematol 1993;85:566–72.
- Heal JM, Cowles J, Masel D, Rowe JM, Blumberg N. Antibodies to plasma proteins: an association with platelet transfusion refractoriness. Br J Haematol 1992;80:83–90.
- Schiffer CA, Keller C, Dutcher JP, Aisner J, Hogge D, Wiernik PH. Potential HLA-matched platelet donor availability for alloimmunized patients. Transfusion 1983;23:286–9.
- Takahashi K, Juji T, Miyazaki H. Determination of an appropriate size of unrelated donor pool to be registered for HLA-matched platelet transfusion. Transfusion 1987;27:394–8.
- Bryant PC, Vayntrub TA, Schrandt HA, Kalil JE, Grumet FC. HLA antibody enhancement by double addition of serum: use in platelet donor selection. Transfusion 1992;32:839–44.
- Rintels PB, Kenney RM, Crowley JP. Therapeutic support of the patient with thrombocytopenia. Transfus Med 1994;8:1131–57.
- Beutler E. Platelet transfusions: the 20,000/
μ L trigger. Blood 1993;81:1411–3. - Freedman J. Platelet crossmatching. In: Rock G, Seghatchian MJ, eds. Quality assurance in transfusion medicine. Vol. 1. Conceptual, serological, and microbiological aspects. Boca Raton, FL: CRC Press, 1992:389–418.
- Morff G, Garratty G, Heal J, et al. Selection of platelets for refractory patients by HLA matching and prospective crossmatching. Transfusion 1992;32:633–40.
- O’Connell BA, Lee EJ, Rothko K, Hussein MA, Schiffer CA. Selection of histocompatible apheresis platelet donors by cross-matching random donor platelet concentrates. Blood 1992;79:527–31.
- Ogden DM, Asfour A, Koller C, Lichtiger B. Platelet crossmatches of single-donor platelet concentrates using a latex agglutination assay. Transfusion 1993;33:644–50.
- Wernet D, Schanaidt M, Mayer G, Northoff H. Serological screening, using three different test systems, of platelet-transfused patients with hematologic-oncologic disorders. Vox Sang 1993;654:108–13.
- Friedberg RC, Donnelly SF, Mintz PD. Independent roles for platelet crossmatching and HLA in the selection of platelets for alloimmunized patients. Transfusion 1994;34:215–20.
- Moroff G, Garratty G, Heal J, et al. Evaluation of platelet crossmatching procedures (abstract). Transfusion 1989; 29:45S.
DOI: https://doi.org/10.21307/immunohematology-2019-801 | Journal eISSN: 1930-3955 | Journal ISSN: 0894-203X
Language: English
Page range: 112 - 124
Published on: Nov 17, 2020
Published by: American National Red Cross
In partnership with: Paradigm Publishing Services
Publication frequency: 4 times per year
Related subjects:
© 2020 G. Garratty, published by American National Red Cross
This work is licensed under the Creative Commons License.